Date post: | 18-Dec-2015 |
Category: |
Documents |
View: | 213 times |
Download: | 0 times |
Pancreas Transplant Pathology: A Surgeon’s
Perspective
Jon Odorico M.D., F.A.C.S.
University of Wisconsin-Madison
Richard Lillehei and William Kelly – First successful pancreas transplant- December 16, 1966
Pancreas Graft Survival UW Experience
1 year rates
SPK 88% P = 0.03
PAN 87%
SPK
PAN
Outline
• Diagnosis and treatment of acute rejection in pancreas transplantation at the University of Wisconsin
• Antibody mediated rejection in SPK recipients
• Chemokine expression in pancreas transplant biopsies
Algorithm for Workup of Elevated Enzymes
Amylase/Lipase
Early < 90 days Late > 90 days
US + Needle Core BiopsyCT Scan
US guided Needle Core Biopsy
Allograft Dysfunction – Indications for Biopsy
• Hyperamylasemia (>100U/L or greater than 2 fold increase) and hyperlipasemia
• Decreased urinary amylase (≥50% baseline)• Mild hyperglycemia (2 consecutive fasting
glucose >200)• Unexplained fever (>38.5ºC)• Tenderness over graft site
Needle Core Biopsy of the PancreasWhy?
• Serum Enzymes - non-specific and only 70% accurate
• No 100% accurate serologic or urinary marker of acute rejection
• Accurate diagnosis of rejection avoids unnecessary over immunosuppression
• Diagnosis of other pathologies
• Significant incidence of isolated pancreas rejection in SPK transplants ~5-15%
Non-Rejection Causes of Elevated Enzymes
• Enteric Drainage• pancreatic enzyme
leak• enteric leak• peripancreatic
infection• pancreatic pseudocyst• small bowel
obstruction
• Bladder Drainage• pancreatic enzyme
leak• bladder anastomosis
leak• peripancreatic
infection• pancreatic
pseudocyst• reflux pancreatitis
48 18
6 7
Biopsy Rejection No Rejection
Se
rum
Am
yla
se
No
rmal
E
lev
ate
d
Normal
Sensitivity = 89% PV+ = 73%Specificity = 28% PV- = 54%
Accuracy = 70%
N=79
-5 0 5 10 15 20 25
Ser
um
Am
ylas
e (U
/ml)
0
100
200
300
400
500
600
700
Amylase
Days post-transplant
-5 0 5 10 15 20 25
Creat
0
1
2
3
4
S
eru
m C
reat
inin
ine
(mg
/dL
)
Real – time Ultrasound Guidance
Treatment of Acute Rejection in Solitary Pancreas Transplant Recipients
UW Experience
184192 195 209
P=NS
CS CS/AB Px
28.3 %
67.4 %
4.3 %
Management of Grade I Pathology and
Outcomes – UW 1997-2007 – 21 of 179 biopsies
If something else is going on no antirejection treatmentIf no other imaging findings or suspected infections, then treat
Percutaneous Needle Core Biopsies UW Experience 1997-2007
Complications
57.9 %
15.8 %
7.8 %
18.4 %
194
145
P = 0.045
Complication rate – 8 (4.5%)
No graft losses
179 biopsies US or CT guided percutaneous needle core biopsy
Summary
• Serum enzyme markers are imperfect
• Rejection grade correlates with outcome
• Grade I pathology in setting of elevated enzymes and no other explanation probably represents early rejection
• Subset of Grade I histopathology may benefit from early treatment
Surveillance or Protocol Biopsies ??
57.9 %
15.8 %
7.8 %
18.4 %
194
145
P = 0.045
What do the infiltrates mean? Are infiltrates pathological in all cases? When and how often?
Increasing evidence of the deleterious effect of subclinical rejection on CAN in kidney transplants
Makes sense when there are poor serological markers of rejection and biopsy is safe , i.e. heart, lung transplantation
?Useful in Solitary Pancreas transplants; probably not necessary in SPK patients
C4d+ Kidney Transplant Rejection in Simultaneous Kidney Pancreas
Transplantation: Differential Effects on
Kidney vs. Pancreas Transplants
LT Chin, M Samaniego, YT Becker, J Odorico,
JD Pirsch, HW Sollinger
Departments of Surgery and Medicine
University of Wisconsin School of Medicine
and Public Health Presented at ATC 2006
Antibody-Mediated Rejection in SPK
• Evaluate effect of AMR on kidney and pancreas transplant function.– identified patients with AMR kidney
– are pancreas transplants susceptible to circulating alloantibody ?
– Does pancreas tx outcome parallel that of the kidney tx ?
Antibody-Mediated Rejection in SPK
• Retrospective database review of all SPK transplants that presented with C4d+ rejection of the kidney allograft from October 2002-October 2005.
• N = 34
Antibody-Mediated Rejection in SPK
• C4d deposition in the peritubular capillaries and kidney allograft dysfunction
• All patients underwent kidney biopsies for elevated Cr (Scr ≥25%).
Antibody-Mediated Rejection in SPK
• Elevated serum amylase or lipase was used as a surrogate marker of pancreas allograft rejection.
• No pancreas biopsies were performed.• Donor specific antibody (DSA-
Luminex®) data were collected whenever available.
Antibody-Mediated Rejection in SPK (n=34)
Early (<90d) Late (>90d)
Number (POD) 8 (7-38) 26 (95-5603)
Cellular rejection 2/8 (25%) 17/26 (65%)
Elevated Amylase 2/8 (25%) 16/26 (62%)
Summary
• AMR (C4d+) occurs early and late after SPK• Approximately 50% have associated cellular
rejection• C4d positivity late post transplant is associated
with worse kidney transplant outcomes• Pancreas function may be unaffected even in the
presence of circulating alloantibody.
AMR Pancreas allograft Grade II C4d+
DSA to A31 and B31
AMR in Pancreas Allograft
• Cell mediated rejection = venous endotheliitis, septal inflammation, lymphocytic infiltrate, eosinophilia
• AMR= unknown but could be that antibody deposition and complement activation in microvasculature compromises blood flow to islets which are supplied by a capillary network much more dense than that of the surrounding exocrine tissue
reference
AMR and Pancreas Transplantation
• Increased expression of C4d has been noted in pancreas allograft biopsies undergoing acute rejection
• Case report of patient with SPK undergoing AMR of both grafts with C4d capillary staining with serum positive for HLA Class II DSA
AMR of Pancreas Allograft
• C4d deposition and AMR have been documented to occur in pancreas allografts
• Interacinar capillaries stain positively
• Standardized criteria for fulfillment of AMR in pancreas allograft should be established
Molecular Markers and Signaling Pathways of Acute Pancreatic
Allograft Rejection Identified by Microarray Analysis
Nathan R. Treff, Lynn M. Jacobson, Drew A. Roenneburg, Stuart J. Knechtle,
Jon S. Odorico
Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Wm.S.Middleton Memorial VA
Hospital, Madison, WI
Chemokines and Rejection
• Shown to play a role in human kidney, heart and hepatic allograft rejection
• Also play a role in islet and pancreas allograft rejection in rodents
• No studies to date have profiled the role of chemokines in human pancreatic allograft rejection
1. Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003; 75:72-78. 2. Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM et al. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003; 75:2044-2047. 3. Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78:65-12 4. Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104:2558-2564.
Conclusions
• Chemokines are upregulated in rejecting pancreatic allografts
• IP-10 possible candidate marker of rejection
• CXCR3+ cells in both normal and rejecting allografts
• Further study of chemokine signaling pathways in pancreas rejection, particularly Grade I and other non-rejection inflammatory states is recommended
Acknowledgements
Tom ChinMillie Saminiego
Jose TorrealbaStuart KnechtleDrew RoennenbergAnna IbeleNathan Treff
UW Biotechnology Center